BiotechTube

AFM24 + SNK01

Phase 1/2Terminated
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Squamous Cell Carcinoma of Head and Neck

Conditions

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Advanced Solid Tumor, Refractory Tumor, Metastatic Tumor

Trial Timeline

Nov 3, 2021 → Sep 21, 2023

NCT ID
NCT05099549

About AFM24 + SNK01

AFM24 + SNK01 is a phase 1/2 stage product being developed by Affimed for Squamous Cell Carcinoma of Head and Neck. The current trial status is terminated. This product is registered under clinical trial identifier NCT05099549. Target conditions include Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05099549Phase 1/2Terminated

Competing Products

20 competing products in Squamous Cell Carcinoma of Head and Neck

See all competitors
ProductCompanyStageHype Score
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
51
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
Cemiplimab + CetuximabEli LillyPhase 2
52
Necitumumab-Gemcitabine-CisplatinEli LillyPhase 2
52
BB-401Benitec BiopharmaPhase 2
44
Ramucirumab + PaclitaxelEli LillyPhase 2
52
Gemcitabine + ACR-368Acrivon TherapeuticsPhase 2
44
CT-P51 + EU-approved KeytrudaCelltrionPhase 3
77
Pembrolizumab + I-DXd + Leucovorin + Levoleucovorin + 5-Fluorouracil (5-FU) + Oxaliplatin + Sacituzumab tirumotecan + Rescue MedicationDaiichi SankyoPhase 1/2
41
Ifinatamab deruxtecan + Docetaxel + Paclitaxel + Irinotecan hydrochloride (HCl)Daiichi SankyoPhase 3
77
I-DXd + Rescue MedicationDaiichi SankyoPhase 1/2
41
Patritumab + Cetuximab + Cisplatin + CarboplatinDaiichi SankyoPhase 1
33
Patritumab Deruxtecan + Platinum-based chemotherapyDaiichi SankyoPhase 3
77
Tivantinib + Placebo + ErlotinibDaiichi SankyoPhase 3
77
Avelumab + enfortumab vedotinAstellas PharmaPhase 2
52
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
52
avelumab + Bempegaldesleukin + talazoparib + enzalutamideAstellas PharmaPhase 1/2
41
Drug Combination TherapySun PharmaceuticalPhase 2
52
Lenvatinib + Pembrolizumab + Docetaxel + Capecitabine + Paclitaxel + Cetuximab + LenvatinibEisaiPhase 2
52

Other Products from Affimed

AFM13Phase 2
44
AFM13Phase 2
44
AFM24 + Atezolizumab 840 MG in 14 ML InjectionPhase 1/2
33
14 mg AFM24 + 40 mg AFM24 + 80 mg AFM24 + 160 mg AFM24 + 320 mg AFM24 + 480 mg AFM24 + 720 mg AFM24Phase 1/2
33
AFM28Phase 1
25